PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 13:45:36 2024-07-04 EDT | ||
| 2.03 EUR | -5.58% |
|
| Current month | +28.48% | ||
| 1 month | -13.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 2.03 | -5.58% |
| 24-07-03 | 2.15 | +27.98% |
| 24-07-02 | 1.68 | +17.48% |
| 24-07-01 | 1.43 | -9.49% |
| 24-06-28 | 1.58 | +3.95% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 01:45 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XA6 |
| ISIN | DE000VD1XA62 |
| Date issued | 2024-03-08 |
| Strike | 1,118 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.95 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.75 € |
|---|---|
| Lowest since issue | 1.27 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.84%
- Stock Market
- Certificates
- Certificat
